Abreos is dedicated to improving the development and commercialization of biopharmaceuticals with our proprietary Veritope platform.
The Veritope technology platform is based on peptide antigen mimetics (mimetopes) that bind to antibodies in the antigen binding site. Veritopes have several advantages as capture agents over antibodies or recombinant protein antigens. They are inexpensive to produce, chemically stable with long shelf lives, and easy to conjugate or integrate into different immunoassays in both laboratory based or point of care settings.
One main application of the Veritope technology is monitoring of biologic drug circulating in blood. Abreos has recently partnered with Lifeassays, a Swedish Point-of-care specialist, and formed the joint venture Aegirbio to commercialize therapeutic drug monitoring diagnostics in the autoimmune, oncology and neurology space.
Drug Monitoring in MS
Ensuring continuity of care for patients living with Multiple Sclerosis (MS) during the COVID-19 pandemic is critical for providers and patients.
moNATor® measures the amount of Tysabri in an MS patient’s blood. This information may help optimize treatment intervals, reducing the risk of exposure to COVID-19 and also potentially reducing the risk of PML